• Publications
  • Influence
Fatigue in rheumatoid arthritis reflects pain, not disease activity.
High fatigue levels characterize RA and are mainly linked to pain and depression, the balance of evidence suggests that fatigue is centrally mediated in established RA. Expand
Fibromyalgic rheumatoid arthritis and disease assessment.
OBJECTIVE We evaluated fibromyalgic RA to determine its clinical impact, identification using core clinical assessments and influence identifying active disease using disease activity scoresExpand
The consequences of rheumatoid arthritis: quality of life measures in the individual patient.
The outcome of RA is greatly improved by current treatment with disease modifying drugs and biologic agents, however, more needs to be done and achieving better results is enhanced by routinely measuring the impact of the disease in routine practice. Expand
Perceived barriers to integrated care in rheumatoid arthritis: views of recipients and providers of care in an inner-city setting
This timely study of the multi-perspective views of recipients and providers of care was conducted during the time of publications of many important reports in the United Kingdom (UK). Expand
Pain Thresholds in Rheumatoid Arthritis: The Effect of Tender Point Counts and Disease Duration
Findings suggest that low pain thresholds reflect “fibromyalgic” RA (many tender points) and central pain sensitization with prolonged disease duration. Expand
Rheumatoid arthritis: non-tumor necrosis factor targets
For patients with rheumatoid arthritis that does not respond to anti-tumor necrosis factor-α treatment, the promising alternatives MRA, abatacept, and rituximab have been tested and it is hoped that these agents will become available shortly. Expand
Depo Provera. Position paper on clinical use, effectiveness and side effects.
Depo Provera (medroxyprogesterone acetate, DMPA) when given as 150 mg by deep intramuscular injection every 12 calendar weeks (84 days+5 days), is a highly effective contraceptive with a very lowExpand
A randomised, double-blind, placebo-controlled trial of a recombinant version of human α-fetoprotein (MM-093) in patients with active rheumatoid arthritis
Evidence of efficacy was observed in the first randomised, controlled trial of MM-093, a recombinant version of human AFP, in patients with RA, suggesting that MM- 093 may have therapeutic potential in RA. Expand
Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies
Treatment intensity has increased over time, disease activity has fallen and there are more remissions, however, these improvements in controlling synovitis have not resulted in comparable reductions in disability measured by HAQ. Expand
Inhibiting costimulatory activation of T cells : a viable treatment option for rheumatoid arthritis?
Abatacept is a fusion protein (cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin [CTLA4Ig]; which blocks the binding of CD28 by avidly binding CD80/86 and has consistently been shown to improve the signs and symptoms of RA in phase II and phase III trials. Expand